TY - JOUR
KW - Hansen disease
KW - Mycobacterium leprae
KW - QcrB inhibitors
KW - Bacteria
KW - leprosy
KW - telacebec
KW - terminal oxidase
KW - Tuberculosis and other mycobacteria
AU - Lahiri R
AU - Adams L
AU - Thomas S
AU - Pethe K
AB - <p>The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials.</p>

BT - Emerging infectious diseases
C1 - <p>https://www.ncbi.nlm.nih.gov/pubmed/35202539</p>

DA - 03/2022
DO - 10.3201/eid2803.210394
IS - 3
J2 - Emerg Infect Dis
LA - eng
N2 - <p>The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials.</p>

PY - 2022
SP - 749
EP - 751
T2 - Emerging infectious diseases
TI - Sensitivity of Mycobacterium leprae to Telacebec.
UR - https://wwwnc.cdc.gov/eid/article/28/3/pdfs/21-0394.pdf
VL - 28
SN - 1080-6059
ER -